ProMetic Life Sciences Inc. Announces Signature of Definitive License Agreement With Kedrion S.p.A. for Two Hyperimmune Products

Published: Feb 26, 2008

MONTREAL, QUEBEC--(Marketwire - February 26, 2008) - ProMetic Life Sciences Inc. ("ProMetic") (TSX: PLI) announced today that it has signed the definitive agreement for development of two hyperimmunes with Kedrion S.p.A. ("Kedrion").

Back to news